The company will receive GMP compliance certificate which will further help to accelerate the business growth across the globe
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
First and only PARP inhibitor to improve overall survival in early breast cancer
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market
Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Aims to become India’s leading cancer testing company
Subscribe To Our Newsletter & Stay Updated
